NexMed, Inc., a developer of innovative pharmaceutical products based on its proprietary, NexACT transdermal drug delivery technology, announced today that Schering AG has terminated its license, supply and distribution agreement for Alprox-TD, NexMed's topical treatment for erectile dysfunction (ED), currently in clinical development. It is NexMed's belief that Alprox-TD is no longer a strategic fit for Schering.
Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=138954)